Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome

Krčméry, V.; Oravcova, E.; Špánik, S.; Mrazova-Studena, M.; Trupl, J.; Kunová, A.; Stopkova-Grey, K; Kukuckova, E.; Krupova, I.; Demitrovicova, A.; Kralovicova, K.

doi:10.1093/jac/41.3.373

Cited by 98 publications

(64 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(p value = 0.017), deserves attention. This fact was verified by other authors; however, this prevalence can depend of the quantity of administrated antibiotics per day, type of drug used (mainly those with broad spectrum), the length of treatment, the Candida specie (C. albicans or non-albicans Candida species), among others (Krcmery Junior et al, 1998;Singh, 2001;Al Thaqafi et al, 2014).…”

Section: Discussionsupporting

confidence: 56%

Exogenous niacin treatment increases NADPH oxidase in kiwifruit

et al. 2018

View full text Add to dashboard Cite

The aim of this study was to evaluate the frequency of Candida species between a non-hospitalized and a hospitalized population. For this purpose, samples of saliva were sampled through sterile swabs, moistened in peptone water and rubbed in the oral cavity of 140 individuals, from which, 70 were hospitalized patients from the Medical Clinic of a Teaching Hospital and the other 70 were non-hospitalized subjects. All saliva samples were plated in Sabouraud Dextrose agar added with Chloramphenicol and incubated at 36 °C for 48 hours. The morphology identification was performed through macroscopic and microscopic characterization, the CHROMagar Candida medium and the VITEK  system Yeast Biochemical Card (bio Mérieux SA, France). The results showed a colonization of Candida spp. in 85.7% the hospitalized individuals, where the species found were C. albicans (60%), C. tropicalis (23.4%), C. krusei (3.3%) and Candida spp. (13.3%). In the non-hospitalized individuals the colonization by Candida spp was 47.1%, and the species found were: C. albicans (45.5%), C.krusei (9.1%), C. guilliermondii (9.1% %), C. tropicalis (3.0%), C. famata (3.0%) and Candida spp. (30.3%). In spite of their presence in oral cavity in both groups, Candida spp. was more frequently isolated in hospitalized individuals, who were 6.73 times more likely to have this fungus in the oral cavity and were 3.88 times more likely to have Candida albicans. Nos indivíduos não-hospitalizados a colonização por Candida spp foi de 47,1%, e as espécies encontradas foram: C. albicans (45,5%), C. krusei (9,1%), C. guilliermondii (9,1%), C. tropicalis (3,0%), C. famata (3,0%) e Candida spp. (30,3%). Apesar de sua presença na cavidade oral em ambos os grupos, Candida spp. foi mais freqüentemente isolada em indivíduos hospitalizados, que foram 6,73 vezes mais propensos a ter este fungo na cavidade oral e foram 3,88 vezes mais propensos a ter Candida albicans. KeywordsPalavras-chave: Candida spp. oral, colonização, pacientes hosptalizados, infecções hospitalares.

show abstract

Section: Discussionsupporting

confidence: 56%

Exogenous niacin treatment increases NADPH oxidase in kiwifruit

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The use of itraconazole and fluconazole prophylaxis in patients with AL have both been assessed in a number of placebo-controlled studies, the results of which have been mixed [2,3,7]. While prophylactic itraconazole and fluconazole may decrease Candida colonization overall, their prophylactic use has been associated with reports of resistant Candida colonization and breakthrough infections as well as significant drug interactions and toxicities [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Invasive fungal disease in patients treated for newly diagnosed acute leukemia

et al. 2010

View full text Add to dashboard Cite

Invasive fungal disease (IFD) is a significant cause of morbidity and mortality in patients undergoing treatment for acute leukemia (AL). Antifungal prophylactic strategies are associated with significant toxicities and cost. We performed a retrospective study of the incidence and risk factors for IFD among patients newly diagnosed with and treated for AL between January 1, 2004 and July 1, 2006. Patient follow up concluded January 1, 2007. Among 231 patients with newly diagnosed AL, 31 (13.4%) developed IFD by the end of follow up, 24 (10.4%) of whom developed IFD within the first 100 days after diagnosis of AL. The cumulative probability of developing IFD was 5.9% by 30 days and 11.1% at 100 days after AL diagnosis. Patients who had persistent leukemia after an initial course of induction chemotherapy were significantly more likely to develop IFD than those who did not have evidence of persistent leukemia (14/65 (21.5%) vs. 15/148 (10.1%), P 5 0.03). In a time-dependent Cox model, the adjusted hazard ratio for developing IFD within the first 100 days of AL diagnosis based on the number of days of neutropenia in that period was 4.85 (95% confidence interval: 1.52, 15.4). Those patients with more days of neutropenia in the first 100 days after AL diagnosis, such as those who did not achieve remission after a first course of induction chemotherapy, were more likely to develop IFD. Am. J. Hematol. 85:695-699, 2010. V

show abstract

“…Disseminated candidiasis is a common, opportunistic infection in neutropenic patients [1][2][3][4][5][6], causing an unacceptable, 50% mortality, despite antifungal therapy [7][8][9][10][11]. As survival of neutropenic patients with hematogenously disseminated fungal infections is linearly related to the patients' granulocyte counts [12,13], exogenous replacement of phagocytes is of great therapeutic potential for these infections.…”

Section: Introductionmentioning

confidence: 99%